MXCT Earnings Date: Nov 10, 2026 (Estimated) — MaxCyte, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is MXCT's next earnings date?
MaxCyte, Inc. (MXCT) is expected to report Q3 2026 earnings on Tuesday, November 10, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $7.4M.
How did MXCT do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), MaxCyte, Inc. posted EPS of -$0.08 versus the -$0.09 estimate, a beat of 20.0%. Revenue was $7.3M against a $6.5M estimate. The stock's 1-day post-earnings move was +9.4%.
How much does MXCT stock move after earnings?
MXCT beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.7% (up or down) in the day after earnings.
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.09 | -0.08 | +20.00% | $7.3M | ✅ Beat | +9.45% | +9.45% | -8.66% |
| 2026-05-12 | Q1 2026 | -0.09 | -0.04 | +55.56% | $9.7M | ✅ Beat | +24.06% | +26.49% | +33.79% |
| 2026-03-24 | Q4 2025 | -0.08 | -0.09 | -12.50% | $7.3M | ❌ Miss | -6.81% | -5.07% | +16.43% |
| 2025-11-12 | Q3 2025 | -0.10 | -0.12 | -20.00% | $6.8M | ❌ Miss | -4.43% | +7.59% | -3.80% |
| 2025-08-06 | Q2 2025 | -0.10 | -0.12 | -20.00% | $8.5M | ❌ Miss | -29.90% | -32.35% | -30.88% |
| 2025-03-11 | Q4 2024 | -0.12 | -0.10 | +16.67% | $8.7M | ✅ Beat | -8.36% | -8.07% | -27.09% |
| 2024-08-06 | Q2 2024 | -0.13 | -0.09 | +30.77% | $10.4M | ✅ Beat | -8.31% | -9.21% | -11.01% |
| 2024-05-07 | Q1 2024 | -0.13 | -0.09 | +30.77% | $11.3M | ✅ Beat | +18.07% | +15.52% | +22.90% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $6.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 61.3% | $4.1M | -22.2% | $15.9M | $5.3M | $5.3M | $4.0M |
| License | 38.7% | $2.6M | -11.5% | — | $4.7M | $2.9M | $2.2M |
By region
Q2 FY26 · $7.3M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 63.7% | $4.6M | -12.9% | $5.3M | $3.8M | $3.9M | $6.6M |
| Non-US | 36.3% | $2.6M | -17.3% | $3.2M | $3.0M | $3.4M | $3.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.